Clinical Trials Browser

Phase 1 × Disulfides × CNS × Clear all

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT02142803 2026-04-29

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

CNSGynecologic

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT02833701 2023-10-24

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

Phase 1 Terminated

9 enrolled

CNS

Glioblastoma, Glioma